Trial Profile
A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
- 11 Dec 2018 Status changed from active, no longer recruiting to completed.
- 07 Jun 2018 Planned End Date changed from 19 Apr 2018 to 1 Oct 2018.